CZC24832 is primarily used in research settings as a selective inhibitor of the p38 mitogen-activated protein kinase (MAPK) pathway. This pathway plays a key role in inflammation and cellular stress responses, making CZC24832 a valuable tool for studying inflammatory diseases, cancer progression, and immune regulation. It has been applied in cellular and preclinical models to investigate the effects of p38 inhibition on cytokine production, cell proliferation, and apoptosis. Due to its potency and selectivity, it aids in validating p38 as a therapeutic target and supports the development of related pharmaceutical agents. Its use is restricted to laboratory and experimental studies, with no current clinical applications.